Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis. OAIJMR 2025, 5 (5), 607-626. https://doi.org/10.37275/oaijmr.v5i5.780.